Compare Novartis AG (NVS) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Consumer Staples Select Sector SPDR Fund — how do they compare? Novartis AG trades at $142.74 (market cap $274.00B), while Consumer Staples Select Sector SPDR Fund trades at $83.05 (market cap $13.44B). The key difference: Novartis AG is far larger — about 20.4× Consumer Staples Select Sector SPDR Fund's market cap, and Novartis AG pays a 3.31% dividend while Consumer Staples Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Consumer Staples Select Sector SPDR Fund for 72 Days on average.
| NVS | XLP | |
|---|---|---|
Market Cap | $274.00B | $13.44B |
Volume | 1,852,137 | 9,437,177 |
Sector | Health | — |
52-Week High | $168.62 | $90.00 |
52-Week Low | $121.80 | $75.61 |
Typical Hold Time | 82 Days | 72 Days |
Enterprise Value | $315.32B | — |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
XLP trades at $81.70, down 0.09% with a bearish technical outlook as moving averages signal selling pressure. The ETF shows strong analyst support with a 100% buy rating from 2 analysts. Recent news highlights XLP's 6.6% YTD gain outperforming discretionary peers, though it faces headwinds from rising interest rates pressuring dividend stocks.
XLP offers defensive exposure to consumer staples with a low 0.08% expense ratio and upcoming dividend. Key risks include persistent inflation and interest rate sensitivity, but the fund's quality holdings provide stability during market volatility. The technical setup suggests near-term consolidation around current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
